No, their program was canned because their Phase I could not in any possible way validate their treatment but they also likely knew it wasn’t going to work or they’d have stuck with and and planned a better trial or used reprogrammed cells.
Their current program is better but was really not a plan original. The leadership team left.
As for “analysts”, you haven’t proved me wrong or even your point. You just waste time.
Companies that fall if major exchanges for a long time do not generally have analysts. That you apparently do not know this speaks more to your lack of knowledge and experience than anything else.
Market Data 
Markets 
AI
